PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9764730-2	1998	This study compares alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyltransferase (GGT) activities in sera of children treated with VPA (n=42), or CBZ (n=36) taken as a monotherapy, with VPA + CBZ combined therapy (n=36).	Valproic Acid	165-168	solute carrier family 17 member 5	Homo sapiens	80-83	
20371285-6	2010	Treatment with valproate sodium obviously decreased the viability of HepG2 cells, accompanied by the increased leakages of ALT, AST and LDH in a dose-dependent manner.	Valproic Acid	15-31	solute carrier family 17 member 5	Homo sapiens	128-131	
9764730-4	1998	The mean catalytic activity of AST was significantly elevated in groups on VPA, CBZ and VPA + CBZ treatment (2.02-, 1.49- and 1.45-fold increase, respectively) as compared to the control values.	Valproic Acid	75-78	solute carrier family 17 member 5	Homo sapiens	31-34	
9764730-4	1998	The mean catalytic activity of AST was significantly elevated in groups on VPA, CBZ and VPA + CBZ treatment (2.02-, 1.49- and 1.45-fold increase, respectively) as compared to the control values.	Valproic Acid	88-91	solute carrier family 17 member 5	Homo sapiens	31-34	
33915122-5	2021	We observed that G-CK significantly ameliorated the decrease of cell viability, elevated ALT, AST and ALP activities, significant oxidative stress, and loss of mitochondrial membrane potential induced by SVP in L02 cells.	Valproic Acid	204-207	solute carrier family 17 member 5	Homo sapiens	94-97	
34282594-4	2021	Results showed: (1) The overall SMD for blood AST, ALT, and GGT levels of VPA monotherapy group versus control group were 0.70 (95% CI=0.31 to 1.09, Z=3.52, p=0.0004), 0.47 (95% CI=- 0.01 to 0.95, Z=1.91, p=0.06), 0.44 (95% CI=0.29 to 0.60, Z=5.55, p<0.00001), respectively.	Valproic Acid	74-77	solute carrier family 17 member 5	Homo sapiens	46-49	
34282594-7	2021	Overall, our results indicated that blood AST and GGT were significantly increased in epileptic minors receiving VPA monotherapy.	Valproic Acid	113-116	solute carrier family 17 member 5	Homo sapiens	42-45	
28205314-6	2018	In LO2 experiment, VPA and its metabolites groups showed an obvious increment of AST, ALT, and LDH in supernate.	Valproic Acid	19-22	solute carrier family 17 member 5	Homo sapiens	81-84	
28782097-12	2017	Sedation was more frequent with higher N-desmethylclobazam levels in adults (p = 0.02), and AST/ALT levels were significantly higher in participants taking concomitant valproate (p &lt; 0.01).	Valproic Acid	168-177	solute carrier family 17 member 5	Homo sapiens	92-95	
28974841-3	2017	AIM: The aim of the study has been to evaluate and compare the effect of CBZ and VPA monotherapy on aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) serum levels in children.	Valproic Acid	81-84	solute carrier family 17 member 5	Homo sapiens	100-126	
28974841-3	2017	AIM: The aim of the study has been to evaluate and compare the effect of CBZ and VPA monotherapy on aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) serum levels in children.	Valproic Acid	81-84	solute carrier family 17 member 5	Homo sapiens	128-131	
28974841-11	2017	CONCLUSION: The levels of enzymes AST and ALT have been elevated statistically significant in VPA group and GGT in CBZ group.	Valproic Acid	94-97	solute carrier family 17 member 5	Homo sapiens	34-37